BioSpace News Archive

Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company, announced it has entered into a placement agency agreement for the purchase and sale of 3,753,558 shares of its common stock at an offering price of $1.065 per share.

Caidya, a leading provider of clinical trial solutions, is proud to announce its recent accreditation in Targeted Source Data Verification (TSDV) from Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry.

Exactech, a global medical technology leader, announced first surgeries debuting the comprehensive Equinoxe® PHx™ System that received FDA 510 clearance in September 2023, marking a significant milestone in advancing shoulder trauma care.

Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced current and potential future clinical directions that can expand the use of its gene therapies to treat additional debilitating diseases.

Luciana Preger credits being exposed to her father’s work at a young age with helping inform her own career in medicine.

Pliant Therapeutics, Inc., announced that on June 10, 2024, it granted stock options to purchase an aggregate of 120,000 shares of common stock upon vesting to Chohee Yun, M.D., the Company’s newly appointed Senior Vice President of Clinical Development as a material inducement to her employment.

Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikefalin for moderate-to-severe pruritus in adult patients with notalgia paresthetica (NP).

Rapport Therapeutics, Inc. (Nasdaq: RAPP) today announced the closing of its initial public offering of 9,200,000 shares of its common stock at a public offering price of $17.00 per share, which includes 1,200,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.

Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced plans to prioritize its pipeline to focus on the development of VTP-300 in CHB and VTP-1000 in celiac disease.